title: Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.
abstract: Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-blind, placebo-controlled trials were pooled for analysis. Overall improvement in depressive symptoms measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the 17-item Hamilton Depression Rating Scale was statistically significant (P<0.05) for vilazodone treatment compared with placebo as early as Week 1 and continued throughout double-blind treatment. Vilazodone treatment compared with placebo showed significant improvement on all 10 individual MADRS symptom items at end of treatment (P<0.01). Rates of response and remission were significantly greater in the vilazodone group relative to the placebo group, with numbers needed to treat ranging from eight to nine for response and 12-17 for remission. Between-group treatment differences in MADRS and the other outcome measures were similar among all depression subgroups, with no consistent pattern associated with depression severity. These findings support the efficacy of vilazodone across a broad range of depressive symptoms and severities for the treatment of major depressive disorder.
authors.affiliation: aNorthwest Clinical Research Center, Bellevue, Washington bDepartment of Psychiatry, Duke University School of Medicine, Durham, North Carolina cAtlanta Institute of Medicine & Research, Atlanta, Georgia dForest Research Institute, Jersey City, New Jersey ePrescott Medical Communications Group, Chicago, Illinois fWorldwide Drug Development, Shelburne, Vermont, USA.
authors.forename: Arif
authors.initials: A
authors.lastname: Khan
authors.forename: Angelo
authors.initials: A
authors.lastname: Sambunaris
authors.forename: John
authors.initials: J
authors.lastname: Edwards
authors.forename: Adam
authors.initials: A
authors.lastname: Ruth
authors.forename: Donald S
authors.initials: DS
authors.lastname: Robinson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome; D000069503:Vilazodone Hydrochloride; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D001572:Benzofurans; D007211:Indoles; D010879:Piperazines; D000069503:Vilazodone Hydrochloride